Patient and donor characteristics (N = 35)
Patient and disease characteristic . | Value . |
---|---|
Median age (range), y | 62 (20-74) |
Sex, n (%) | |
Male | 21 (60) |
Female | 14 (40) |
Diagnosis, n(%) | |
Mycosis fungoides | 13 (37) |
Stage IIB* | 7 (20) |
Stage IVA | 6 (17) |
Large cell transformation | 12 (34) |
Skin only | 8 (23) |
Skin plus extracutaneous site | 4 (11) |
Sézary syndrome | 22 (63) |
Stage IVA | 17 (49) |
IVB | 5 (14) |
Large cell transformation | 8 (23) |
Skin only | 3 (9) |
Extracutaneous site only | 3 (9) |
Skin plus extracutaneous site | 2 (5) |
Retro-CLIPI, n (%)† | |
High risk | 18 (52) |
Intermediate risk | 13 (37) |
Low risk | 4 (11) |
Time from diagnosis to allogeneic HCT, median (range), mo | 40 (9-152) |
<24, n (%) | 12 (34) |
≥24, n (%) | 23 (66) |
No. of previous systemic therapies, median (range) | 5 (2-13) |
Active disease at the time of conditioning, n (%) | |
Skin | 35 (100) |
Blood | 12 (34) |
Lymph node | 22 (63) |
Visceral‡ | 5 (14) |
Donor, n (%) | |
Sibling | 13 (37) |
Unrelated | 22 (63) |
Matched | 15 (43) |
Mismatched§ | 7 (20) |
Donor–recipient CMV status, n (%) | |
Donor and/or recipient seropositive | 27 (77) |
Donor and recipient seronegative | 8 (23) |
Patient and disease characteristic . | Value . |
---|---|
Median age (range), y | 62 (20-74) |
Sex, n (%) | |
Male | 21 (60) |
Female | 14 (40) |
Diagnosis, n(%) | |
Mycosis fungoides | 13 (37) |
Stage IIB* | 7 (20) |
Stage IVA | 6 (17) |
Large cell transformation | 12 (34) |
Skin only | 8 (23) |
Skin plus extracutaneous site | 4 (11) |
Sézary syndrome | 22 (63) |
Stage IVA | 17 (49) |
IVB | 5 (14) |
Large cell transformation | 8 (23) |
Skin only | 3 (9) |
Extracutaneous site only | 3 (9) |
Skin plus extracutaneous site | 2 (5) |
Retro-CLIPI, n (%)† | |
High risk | 18 (52) |
Intermediate risk | 13 (37) |
Low risk | 4 (11) |
Time from diagnosis to allogeneic HCT, median (range), mo | 40 (9-152) |
<24, n (%) | 12 (34) |
≥24, n (%) | 23 (66) |
No. of previous systemic therapies, median (range) | 5 (2-13) |
Active disease at the time of conditioning, n (%) | |
Skin | 35 (100) |
Blood | 12 (34) |
Lymph node | 22 (63) |
Visceral‡ | 5 (14) |
Donor, n (%) | |
Sibling | 13 (37) |
Unrelated | 22 (63) |
Matched | 15 (43) |
Mismatched§ | 7 (20) |
Donor–recipient CMV status, n (%) | |
Donor and/or recipient seropositive | 27 (77) |
Donor and recipient seronegative | 8 (23) |